Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
This article was originally published in The Pink Sheet Daily
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.
You may also be interested in...
In One Day, Change At Biotechs: Leiden To Replace Emmens At Vertex And At Amgen, Bradway Will Become CEO
Board member Jeffrey Leiden, who oversaw the commercialization of Humira at Abbott, will succeed Matthew Emmens as Vertex CEO next February.
Study presented at AASLD provides evidence of the potential value of genotyping patients prior to treatment with new protease inhibitors; Medco ready to start testing program.
High unmet medical need, a genetically targeted patient population and the drug's biological rationale could combine for a faster-than-six-month approval for the novel, disease-modifying therapy.